Business
Novocure to Participate in 2026 Leerink Global Healthcare Conference
BAAR, Switzerland, February 27, 2026--Novocure to Participate in 2026 Leerink Global Healthcare Conference
About this update from Novocure Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2785,"height":407,"url":"https://media.zenfs.com/en/business-wire.com/810a087910eabeaeeb570704a7d480f1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ERuFOwcog8OerUugnfCksw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/810a087910eabeaeeb570704a7d480f1","width":960,"height":140},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/q3htKu0KJnPitWZ7aMTXDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/810a087910eabeaeeb570704a7d480f1","width":1200,"height":175}},"lazy":false},{"type":"text","content":"BAAR, Switzerland, February 27, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 11:20 a.m. EST, as well as one-on-one meetings with investors throughout the event.","length":410,"tagName":"p"},{"type":"text","content":"A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.","length":225,"tagName":"p"},{"type":"text","content":"About NovocureNovocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.","length":654,"tagName":"p"},{"type":"text","content":"Novocure’s global headquarters is located in Baar, Switzerland, with U.S. headquarters located in Portsmouth, New Hampshire and research and development facilities locate...